FDA Expands Sevabertinib to First Line HER2 Mutated Lung Cancer

What changed

On 9 September 2026, the U.S. Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.) for adult patients with locally advanced or metastatic non squamous non small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA authorized test, and who have not received prior systemic therapy.

The decision expands an existing accelerated approval that covered patients who had already received prior systemic therapy. In the first line cohort of 69 evaluable patients, the confirmed objective response rate was 75 percent with a 95 percent confidence interval of 64 to 85. Among responders, 73 percent had duration of response at least six months and 38 percent at least twelve months.

Why it matters

HER2 mutated lung cancer has historically lacked targeted first line options comparable to other oncogene driven NSCLC subsets. A 75 percent response rate in treatment naive patients gives oncology formularies a kinase inhibitor label backed by blinded independent central review, priority review, breakthrough therapy designation, and orphan drug designation. For precision medicine teams, the approval reinforces demand for FDA authorized HER2 mutation assays before first line chemo immunotherapy defaults.

Who is affected

Oncology pharmacy and therapeutics committees, molecular diagnostics vendors, lung cancer trial sponsors comparing sevabertinib combinations, and payer teams modeling kinase inhibitor budgets.

What to do next

Audit current NSCLC reflex testing panels to confirm HER2 tyrosine kinase domain mutations are reported with an FDA authorized companion diagnostic before first line treatment selection meetings.

What to watch

Confirmatory trial readouts required under accelerated approval, competitor HER2 directed programs in earlier lines, and real world duration of response outside the 69 patient first line cohort.

Sources

1. Primary. U.S. FDA, FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non squamous non small cell lung cancer (9 September 2026). Indication expansion, ORR, and DOR statistics.